For Immediate Release

Contact: Brian Hansen
Total Site, Inc.
303-415-9404
bhansen@totalsite.com

Colorado Company Joins Fight Against Heart Disease
Launches New Web Site

WESTMINSTER, CO - America's number one killer is facing a new foe. Myogen, a biopharmaceutical company based in Westminster, Colorado, is exploring novel therapies to treat heart failure. The company launched its web site, http://www.myogen.com, today.

Founded in 1996, Myogen's successful research and development are based on three key assets. One, the scientific and clinical teams maintain extensive knowledge of the biochemistry and clinical treatment of heart muscle disease and the clinical syndrome of heart failure. Two, Myogen maintains a large and well-documented human heart tissue bank. And three, the research team has made a series of scientific discoveries that define the molecular mechanisms by which human myocardial failure occurs. All this adds up to an extremely positive outlook for the company's future.

Myogen already has one product, Perfan I.V., on the market and two more in the pipeline. Perfan I.V. is registered and sold in Europe for the treatment of acute decompensated heart failure.

These products, as well as research and development and financial reports are available at the new site. Users can check on the latest news about new licensing agreements or explore specific research programs such as the Fetal Gene Program.

Myogen gave the web project to fellow Colorado company, Total Site, Inc. The site's vast amounts of information required the developer's experience in providing logical web architecture. Based in Boulder, Total Site has been tapped for a large number of corporate web projects. In addition to corporate web identities, Total Site also specializes in ecommerce solutions, web application development, internet marketing and email management.